1. Introduction {#sec1-molecules-18-01728}
===============

Tuberculosis (TB) remains an international public health burden around the World. Current global estimates indicate that one third of the global population was infected with TB. In 2010 there were still 8.8 million new cases of TB, 1.1 million deaths from TB among HIV-negative people and an additional 0.35 million deaths from HIV-associated TB \[[@B1-molecules-18-01728]\]. China has the largest population account for 20% of the world total. TB remains a big threat to this country. The report of the 4th National Epidemiological Sampling Survey of TB in China stated that the infection rate of TB in the country was 44.5% (about 550 million) \[[@B2-molecules-18-01728]\]. Although currently available drugs kill most isolates of *Mycobacterium tuberculosis*, strains resistant to each of them have emerged, and multiply resistant strains are increasingly widespread, 500,000 of whom are multidrug-resistant (MDR) \[[@B3-molecules-18-01728]\]. The growing problem of drug-resistance combined with the deadly link between TB and HIV infection underscore the urgent need for new anti-TB agents.

4-Deoxybostrycin ([Figure 1](#molecules-18-01728-f001){ref-type="fig"}A), a natural anthraquinone compound, was first isolated from the fungus *Alternaria eichhorniae* \[[@B4-molecules-18-01728]\]. Its structure was identified by interpretation of spectral data \[[@B5-molecules-18-01728],[@B6-molecules-18-01728]\]. Nigrosporin ([Figure 1](#molecules-18-01728-f001){ref-type="fig"}B) is the deoxy-derivative of 4-deoxybostrycin. It was also a natural product which was first isolated from the fungus *Nigrospora oryzae*. Its structure was identified by interpretation of spectral data \[[@B7-molecules-18-01728]\]. Recently we obtained 4-deoxybostrycin and nigrosporin isolated from the fungus *Nigrospora* sp. \[[@B8-molecules-18-01728],[@B9-molecules-18-01728]\]. It has been reported that 4-deoxybostrycin has various biological properties, including antibacterial \[[@B8-molecules-18-01728]\], phytotoxic \[[@B4-molecules-18-01728],[@B10-molecules-18-01728]\], antimalarial \[[@B11-molecules-18-01728]\], and cytotoxic activities \[[@B8-molecules-18-01728],[@B12-molecules-18-01728]\]. However, its anti-mycobacterial activity is not well investigated.

In this study, we tested it and its derivative's anti-mycobacterial activity *in vitro*. We first screened and quantitated the anti-mycobacterial activity of the compound and its derivative with the Kirby-Bauer disk diffusion susceptibility test and the absolute concentration susceptibility test respectively. Then we detected the differential expression of *M. tuberculosis* genes after treatment with 4-deoxybostrycin by gene chips and confirmed the results with quantitative real-time polymerase chain reaction (qRT-PCR) experiments.

2. Results and Discussion {#sec2-molecules-18-01728}
=========================

2.1. Preparation of 4-Deoxybostrycin and Nigrosporin {#sec2dot1-molecules-18-01728}
----------------------------------------------------

4-deoxybostrycin and nigrosporin were isolated from the mangrove endophytic fungus *Nigrospora* sp. collected from the South China Sea as previously reported \[[@B8-molecules-18-01728],[@B9-molecules-18-01728]\].

2.2. The In Vitro Anti-Mycobacterial Activity of the Compounds {#sec2dot2-molecules-18-01728}
--------------------------------------------------------------

The *in vitro* anti-mycobacterial activity of the compounds was first screened with the Kirby-Bauer disk diffusion susceptibility test. 4-Deoxybostrycin and nigrosporin showed an inhibition zone size of 30 mm and 27 mm, respectively, against *M. bovis* BCG in 4 weeks-cultivated Middlebrook 7H11 agar plates. Their minimum inhibitory concentration (MIC) values against a series of mycobacterial strains were also determined in Middlebrook 7H11 agar slants with the absolute concentration susceptibility test, and these were compared with commercial control drugs including streptomycin (SM), isoniazid (INH), rifampicin (RFP), and ethambutol (EMB). As shown in [Table 1](#molecules-18-01728-t001){ref-type="table"}, the two compounds both showed inhibitory effects against mycobacteria. Moreover, against two MDR *M. tuberculosis* clinical isolates K2903531 and 0907961, 4-deoxybostrycin exhibited a good inhibition, which even better than that of the first line anti-TB agents.

2.3. 4-Deoxybostrycin-Induced Alterations in Gene Expression in *M. tuberculosis* H37Rv

According to the study above, 4-deoxybostrycin exhibited a better anti-mycobacterial activity. To find out the differentially expressed genes after treatment with 4-deoxybostrycin and investigate the possible anti-mycobacterial mechanism of the compound at the gene level, we tested the differences of gene expression in *M. tuberculosis* H37Rv just exposed to 4-deoxybostrycin by using the *M. tuberculosis* cDNA microarrays which consists of 3,875 predicted open reading frames of the *M. tuberculosis* H37Rv strain (13). Of all genes tested, 119 genes were significantly different in *M. tuberculosis* H37Rv exposed to 4-deoxybostrycin compared to untreated control. We found that 52 were significantly increased, and 67 were significantly decreased in the 4-deoxybostrycin treatment group. There were 46 functionally known genes, including 24 up-regulated genes and 22 down-regulated genes involved in nucleotide, lipid, energy, coenzyme, carbohydrate metabolism, information storage and processing, and other cellular processes ([Table 2](#molecules-18-01728-t002){ref-type="table"}).

The tuberculosis cDNA gene chips employed in our study were based on the *M. tuberculosis* H37Rv gene sequence. The functions of these differentially expressed genes included nucleotide, lipid, coenzyme, and carbohydrate metabolism; energy production; information storage and processing; and cellular processes. Therefore, we conclude that 4-deoxybostrycin exerts its anti-TB function through multiple targets. We screened several differentially expressed genes from the compound. 4-deoxybostrycin successfully inhibited drug-resistant *M. tuberculosis* isolates, which allows for new study into the genes affected by the compound to promote the discovery of new anti-*M. tuberculosis* mechanisms and targets. Meanwhile, we can justify and predict the compound's toxicity and determine if there will be cross-resistance with other anti-TB drugs by examining the affected genes.

2.4. 4-Deoxybostrycin-Induced Expression Changes of Some Genes Were Confirmed with qRT-PCR {#sec2dot4-molecules-18-01728}
------------------------------------------------------------------------------------------

Total RNA from *M. tuberculosis* H37Rv from either 4-deoxybostrycin-treated or untreated control cultures used for microarray experiments was converted to cDNA, and the expressions of 36 functionally known genes were confirmed with qRT-PCR. Gene expression was normalised with *M. tuberculosis* housekeeping genes. There were only six genes (Rv1518, Rv0282, gnd2, Rv3044 \[fecB\], Rv3673c, and Rv1372 \[pks18\]) that were significantly differentially expressed compared to untreated control cultures ([Table 3](#molecules-18-01728-t003){ref-type="table"}).

We performed qRT-PCR to verify the gene chips. The results showed that their consistency was just 12.3%, indicating that screening through gene chips involves high experimental error that necessitates further confirmation. This array consists of 3,875 predicted open reading frames of the *M. tuberculosis* H37Rv strain \[[@B13-molecules-18-01728]\]. We identified six genes that were significantly differentially expressed compared to untreated control cultures. Gene product of Rv1518 is conserved hypothetical protein, possible glycosyl transferase involved in exopolysaccharide synthesis, was identified in the cell membrane fraction of *M. tuberculosis* H37Rv \[[@B14-molecules-18-01728]\]. Gene product of Rv0282 is identified in the membrane fraction of *M. tuberculosis* H37Rv using 1D-SDS-PAGE and uLC-MS/MS \[[@B15-molecules-18-01728]\], and its function is not clearly understood. Rv3044, probable fecB, FeIII dicitrate-binding periplasmic lipoprotein (see citation below), identified in immunodominant fractions of *M. tuberculosis* H37Rv culture filtrate using 2D-LPE, 2D-PAGE, and LC-MS or LC-MS/MS \[[@B13-molecules-18-01728]\]. Rv3673c, possible membrane protein, thioredoxin-like protein (thiol-disulfide interchange protein) \[[@B16-molecules-18-01728]\]. Rv1372, conserved hypothetical protein, function of which is not clearly understood \[[@B17-molecules-18-01728]\]. The present study provides a useful experiment basis for exploitation of correlative new drugs against TB and for finding out new targets of anti-mycobacterial therapy.

3. Experimental {#sec3-molecules-18-01728}
===============

3.1. Preparation and Structure of 4-Deoxybostrycin and Nigrosporin {#sec3dot1-molecules-18-01728}
------------------------------------------------------------------

4-deoxybostrycin and nigrosporin were extracted from the fungal fermentation broth by solvent extraction method then purified through chromatography including silica gel column chromatography, ODS column chromatography and HPLC. All reagents and solvents used in experiments were commercially available. Melting points were measured on an X-4 micromelting point apparatus and were uncorrected. IR spectra were measured on a Bruker Vector 22 spectrophotometer (Bruker Corporation, Fremont, CA, USA) using KBr pellets. NMR spectra were determined on a Varian Inova-500 NB spectrometer or Bruker AV-400 NB spectrometer (Bruker Corporation) in CDCl3 or DMSO-*d*6 using TMS as internal standard, and coupling constants (*J*) are in Hz. EI mass spectra were recorded on a DSQ mass spectrometer and ESI mass spectra were obtained on a LCQ DECA XP LC-MS mass spectrometer.

4-deoxybostrycin Red solid (MeOH); mp: 224--225 °C; \[α$\rbrack_{D}^{25}$ +90.9 (c 1.1 × 10^−4^, MeOH); ^1^H-NMR (300 MHz, DMSO-*d*~6~): δ 13.18 (s, 1H, 9-OH), 12.62 (s, 1H, 10-OH), 6.42 (s, 1H, 7-H), 4.82 (*d*, *J* = 5.1 Hz, 1H, 2-OH), 4.48 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.61 (dt, *J* = 7.3, 5.1 Hz, 1H, 2-H), 2.82 (dd, *J* = 18.3, 5.1 Hz, 1H, 1-H~b~), 2.77 (d, *J* = 18.1 Hz, 1H, 4-H~b~), 2.64 (dd, *J* = 18.3, 7.3 Hz, 1H, 1-H~a~), 2.56 (d, *J* = 18.1 Hz, 1H, 4-H~a~), 1.18 (s, 3H, 3-CH~3~); ^13^C-NMR (125 MHz, DMSO-*d*~6~): δ 183.39 (C-8), 176.35 (C-5), 161.31 (C-10), 160.38 (C-6), 159.67 (C-9), 138.88 (C-9a), 136.33 (C-4a), 109.47(C-7), 108.97 (C-10a), 106.85 (C-8a), 70.12 (C-2), 68.81 (C-3), 56.95 (6-OMe), 35.72 (C-4), 29.91 (C-1), 25.39 (3-CH~3~); EIMS *m/z* 320 \[M\]^+^ (100), 302 (41), 287 (30), 259 (61), 247 (96), 234 (20), 219 (45), 205 (10).

Nigrosporin Yellow solid (MeOH); mp: \>300 °C; \[α$\rbrack_{D}^{25}$ +131.4 (c 1.75 × 10^−4^, MeOH); ^1^H-NMR (400 MHz, DMSO-*d*~6~): δ 12.67 (s, 1H, 9-OH), 7.26 (s, 1H, 10-H), 6.29 (s, 1H, 7-H), 4.76 (d, *J* = 3.6 Hz, 1H, 2-OH), 4.39 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.66 (m, 1H, 2-H), 2.93(d, *J* = 17.5 Hz, 1H, 4-H~b~), 2.85 (dd, *J* = 18.4, 4.9 Hz, 1H, 1-H~b~), 2.77 (d, *J* = 17.5 Hz, 1H, 4-H~a~), 2.69 (dd, *J* = 18.4, 7.1 Hz, 1H, 4-H~a~), 1.17 (s, 3H, 3-CH~3~); ^13^C-NMR (100 MHz, DMSO-*d*~6~): δ 190.76 (C-8), 178.79 (C-5), 161.11 (C-6), 158.31 (C-9), 144.01 (C-4a), 131.70 (C-9a), 127.95 (C-10a), 119.37 (C-10), 110.65 (C-8a), 109.33 (C-7), 70.51 (C-2), 69.41 (C-3), 56.78 (6-OMe), 41.67 (C-4), 29.75 (C-1), 25.07 (3-CH~3~); EIMS *m/z* 304 \[M\]^+^ (34), 286 (85), 271 (100), 257 (57), 243 (94), 229 (45), 215(54), 201 (23).

3.2. Bacterial Strains and Culture Conditions {#sec3dot2-molecules-18-01728}
---------------------------------------------

The following mycobacterial strains were used in this study, *M. bovis* BCG (strain Pasteur, ATCC 35734) and a virulent reference strain of *M. tuberculosis* H37Rv (ATCC 27294) which were obtained from the China Center of Medical Culture Collection; two MDR *M. tuberculosis* clinical isolates (K2903531, resistant to SM, INH, RFP and EMB; 0907961, resistant to SM and EMB), a drug-resistant *M. tuberculosis* clinical isolate (K0903557, resistant to INH), a drug-sensitive *M. tuberculosis* clinical isolate (0907762), and an extensively drug-resistant (XDR) clinical *M. avium-intracellulare* isolate (K0803182, resistant to SM, INH, RFP, LVFX, protionamide and isoniazid aminosalicylate), and *M. avium* reference strain (ATCC 25291) and *M. intracellulare* reference strain (ATCC 13950), which were kindly provided by the Guangzhou Chest Hospital, China.

There were two culture media used in our experiments including Middlebrook 7H9 (Bio-Rad, Richmond, CA, USA) and Middlebrook 7H11 (Bio-Rad). Middlebrook 7H9 broth was used for the cultivation of *M. tuberculosis* H37Rv to test the differential expression of genes *in vitro*. Middlebrook 7H11 was used for the cultivation of all mycobacterial strains in Kirby-Bauer disk diffusion susceptibility test (agar plate) or the absolute concentration susceptibility test (agar slant) to screen or quantify *in vitro* the anti-mycobacterial activity (including MIC) of the compounds.

3.3. The Kirby-Bauer Disk Diffusion Susceptibility Test {#sec3dot3-molecules-18-01728}
-------------------------------------------------------

Bacterial suspension was prepared from 10-days old *M. bovis* BCG or other mycobacterial strain cultures grown on Middlebrook 7H11 agar slant, supplemented with 10% oleic acid, bovine serum albumin (fraction V), dextrose, and catalase (OADC; Remel, Lenexa, KS, USA) and 0.05% Tween 80. The turbidity of the suspension was adjusted to a McFarland no. 3 (9 × 10^8^ CFU/mL) in sterile normal saline. The bacteria was spread on Middlebrook 7H11 agar plates, then discs with 100 μg different kinds of compounds were placed on the plates. All plates were incubated at 37 °C for 4--8 weeks before measuring the diameter of the zone of inhibition of each chemical.

3.4. The Absolute Concentration Susceptibility Test {#sec3dot4-molecules-18-01728}
---------------------------------------------------

Middlebrook 7H11 agar medium was prepared and sterilized by autoclaving at 121 °C for 15 min. Sterilized medium was supplemented with 10% of sterile OADC at 55--60 °C. The final desired concentrations (100, 60, 50, 40, 30, 20, 15, 10 and 5 μg/mL, respectively, or finer range between 0.1--60 μg/mL) of chemicals were added to respective flasks and poured into 15 mL sterile screwcap plastic test tubes respectively. Upon solidification of medium and preparation of agar slant, the tubes, with or without chemical, were inoculated with 30 μL of 10-fold dilution (3 × 10^7^ CFU/mL) of each mycobacterial strain's suspension equivalent to a McFarland 1.0 standard (3 × 10^8^ CFU/mL). All the tubes were then incubated at 37 °C for 4--8 weeks. The slants were read when all the cultures had grown on the control slant. If there was no colony grown in the presence of the compound, the lowest concentration of the compound was considered as the MIC.

3.5. Determination of the Differential Expressed Genes by Gene Chips and qRT-PCR {#sec3dot5-molecules-18-01728}
--------------------------------------------------------------------------------

### 3.5.1. RNA Isolation of *M. tuberculosis* H37Rv {#sec3dot5dot1-molecules-18-01728}

Bacterial liquid from the Middlebrook 7H9 medium at log growth period was taken. The experimental group was treated with 4-deoxybostrycin at the final concentration of MIC concentration. The control group was treated with equal volume of solvent which was used to dissolve and dilute the compound. Both groups were incubated for 2 h at 37 °C and then harvested by centrifugation (6000 × g, 5 min). Pellets were resuspend in 95 °C preheated 200 μL MaxBacterial Enhancement Reagent (Invitrogen, Carlsbad, CA, USA) and incubated at 95 °C for 4 min, then transferred to 2 mL screwcap tubes containing 1 ml Trizol reagent (Invitrogen) and 0.5 mL of 0.1-mm-diameter glass beads. Cells were disrupted by strenuous vibration \[[@B18-molecules-18-01728]\]. The RNA was extracted according to the Trizol manufacturer's instructions.

To remove residual DNA, samples were treated with Turbo DNAse (Ambion, Austin, TX, USA). The integrity of all RNA samples was checked by nondenaturing agarose gel electrophoresis, with RNA concentration quantified by spectrophotometry.

### 3.5.2. Preparation of Labelled cDNA of Bacteria for Gene Chips and Hybridization {#sec3dot5dot2-molecules-18-01728}

cDNA was synthesized and fluorescently labelled by a direct procedure. The RNA was labelled by Cy5-dUTP in untreated control group and Cy3-dUTP in treated group respectively. After heating at 70 °C for 3 min and chilling on ice, the RNA was reverse transcribed. The labelled cDNA probes were then purified and concentrated using the MiniElute Cleanup kit (Qiagen, Valencia, CA, USA). The total purified cDNA probes were added to the arrays in a hybridization solution containing a final concentration of 5 × SSPE, 2% SDS, 5 × Denhardt's regent. The arrays were pre-hybridized with denatured salmon sperms DNA at 65 °C for 1 h and then were hybridized overnight at 65 °C, using roller bottles at 6 r.p.m. After removing the hybridized mixture, the chips were washed with preheated Panorama^®^ Microbial Array wash solution (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions.

### 3.5.3. Microarray Data Analysis {#sec3dot5dot3-molecules-18-01728}

Microarray slides were scanned using a Typhoon™ FLA 9000 Biomolecular Imager (GE Healthcare, Uppsala, Sweden). Images were processed and the fluorescent intensity of each spot was quantified using the ImageQuant TL v2005 software. Four independent biological replicates were analyzed for each compound group, one swap-dye experiment was included. Median intensity values were corrected by background subtraction. Further analysis was performed using SPSS software (version 16.0 for Windows; SPSS Inc., Chicago, IL, USA). Data was represented by the spot signal as a percentage of the total signal from all spots on the array. Cy5/Cy3 intensity ratios were determined using normalized values. For each gene, the geometric mean was calculated from the intensity ratios of the 2 replicates and the result value was used to determine differences in mRNA abundance between treated group and untreated group. Genes were classified as differentially expressed if the Cy5/Cy3 intensity ratios were out of the range of 0.67--1.5. Statistical significance of the chosen genes was verified by following real-time PCR.

3.6. Detection of Differential Expressed Genes by qRT-PCR {#sec3dot6-molecules-18-01728}
---------------------------------------------------------

Total RNA was extracted from the treated and untreated *M. tuberculosis* H37Rv as mentioned above. cDNA was synthesized from total RNA using random hexamers. The design of primers ([Table 4](#molecules-18-01728-t004){ref-type="table"}) used for real-time PCR was based on the published genome sequence of *M. tuberculosis* H37Rv \[[@B13-molecules-18-01728]\]. Real-time PCR was performed using SYBR Green (Roche, Mannheim, Germany) in a LightCycler 4800 (Roche, Germany). The end point used in the real-time RT-PCR quantification, Ct, was defined as the PCR cycle number at which each assay target reached the threshold. The data represented the fold change in mRNA expression relative to *M. tuberculosis* incubated with medium alone. To calibrate each amplification result, three *M. tuberculosis* housekeeping genes including 10Sa RNA (<http://www.ncbi.nlm.nih.gov/pubmed/1371186>), MPT70 (<http://www.ncbi.nlm.nih.gov/protein/BAA07184.1>) and diaminopimelate decarboxylase (<http://www.ncbi.nlm.nih.gov/protein/YP_006514669.1>) served as correction factors. The ratio of the same gene expression between the treated and untreated *M. tuberculosis* H37Rv was calculated by the amplified gene copies of 4-deoxybostrycin-treated bacteria divided by the amplified gene copies of untreated bacteria. The criteria used to justify differential expression was the same as above gene chips, *i.e.*, genes were classified as differentially expressed if the ratios were out of the range of 0.67--1.5.

4. Conclusions {#sec4-molecules-18-01728}
==============

4-Deoxybostrycin is a natural anthraquinone compound isolated from the mangrove endophytic fungus *Nigrospora sp*. collected from the South China Sea. It showed a good anti-TB activity *in vitro*. Moreover, 4-deoxybostrycin could affect the expression of *M. tuberculosis* H37Rv genes which are involved in nucleotide, lipid, energy, coenzyme, carbohydrate metabolism, information storage and so on. Perhaps 4-deoxybostrycin could be a candidate for the development of new agents to treat TB.
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![The structure of 4-deoxybostrycin (**A**) and nigrosporin (**B**).](molecules-18-01728-g001){#molecules-18-01728-f001}

molecules-18-01728-t001_Table 1

###### 

MIC of 4-deoxybostrycin and nigrosporin to BCG, *M. tuberculosis* and other mycobacterial strains.

  Bacterial strains                                                                                                                                                                     MIC (μg/mL) ^a^                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- -------- ------- ------- ------- -------
  *M. bovis* BCG (strain Pasteur, ATCC 35734)                                                                                                                                           39                15       0.1     0.1     0.05    1.6
  *M. tuberculosis* H37Rv reference strain (ATCC 27294)                                                                                                                                 15                20       0.4     0.05    \<0.1   6.4
  Clinical MDR *M. tuberculosis* strain (K2903531, resistant to SM, INH, RFP and EMB)                                                                                                   \<5               30       \>20    \>3.2   \>20    7.5
  Clinical MDR *M. tuberculosis* strain (0907961, resistant to SM and EMB)                                                                                                              10                20       20      0.1     0.1     \>6.4
  Clinical drug-resistant *M. tuberculosis* strain (K0903557, resistant to INH)                                                                                                         30                30       0.2     2.5     0.25    \<1.6
  Clinical drug-sensitive *M. tuberculosis* strain (0907762)                                                                                                                            10                ND ^b^   \<0.1   0.025   10      \<1.6
  *M. avium* reference strain (ATCC 25291)                                                                                                                                              \>60              \>60     20      5       30      3
  *M. intracellulare* reference strain (ATCC 13950)                                                                                                                                     \>60              \>60     \>20    8       \>50    2.5
  Clinical extensively drug-resistant (XDR) *M. avium-intracellulare* strain (K0803182, resistant to SM, INH, RFP, levofloxacin \[LVFX\], protionamide and isoniazid aminosalicylate)   \>60              \>60     0.1     5       6.4     7.5

^a^ MIC (minimum inhibitory concentration) is defined as the lowest concentration inhibiting 100% of the inoculum relative to controls. ^b^ ND: not done.

molecules-18-01728-t002_Table 2

###### 

Detection of number and functions of differentially expressed *M. tuberculosis* H37Rv genes induced by 4-deoxybostrycin with *M. tuberculosis* cDNA microarray and their functions.

  Gene name   Synonym   Mean of ratio   SD     Functional Category
  ----------- --------- --------------- ------ -------------------------------------------------------------------------------------
  Rv0907      \-        0.46            0.03   Cellular processes: Cell envelope biogenesis, outer membrane
  Rv1518      \-        0.51            0.05   Cellular processes: Cell envelope biogenesis, outer membrane
  cmaA1       Rv3392c   1.88            0.08   Cellular processes: Cell envelope biogenesis, outer membrane
  Rv1212c     \-        1.98            0.21   Cellular processes: Cell envelope biogenesis, outer membrane
  fecB        Rv3044    1.66            0.04   Cellular processes: Inorganic ion transport and metabolism
  ctpG        Rv1992c   1.60            0.05   Cellular processes: Inorganic ion transport and metabolism
  cysA        Rv2397c   1.78            0.08   Cellular processes: Inorganic ion transport and metabolism
  Rv0282      \-        0.47            0.04   Cellular processes: Posttranslational modification, protein turnover, chaperones
  Rv3673c     \-        1.78            0.09   Cellular processes: Posttranslational modification, protein turnover, chaperones
  Rv2264c     \-        1.79            0.02   Cellular processes: Posttranslational modification, protein turnover, chaperones
  htpX        Rv0563    1.90            0.15   Cellular processes: Posttranslational modification, protein turnover, chaperones
  narL        Rv0844c   0.45            0.10   Cellular processes: Signal transduction mechanisms
  Rv3132c     \-        1.58            0.04   Cellular processes: Signal transduction mechanisms
  Rv1354c     \-        2.59            0.25   Cellular processes: Signal transduction mechanisms
  ogt         Rv1316c   0.42            0.04   Information storage and processing: DNA replication, recombination and repair
  ligB        Rv3062    1.78            0.06   Information storage and processing: DNA replication, recombination and repair
  Rv0922      \-        1.99            0.21   Information storage and processing: DNA replication, recombination and repair
  rpsD        Rv3458c   0.42            0.03   Information storage and processing: Translation, ribosomal structure and biogenesis
  rpsS        Rv0705    0.44            0.07   Information storage and processing: Translation, ribosomal structure and biogenesis
  prfB        Rv3105c   0.45            0.02   Information storage and processing: Translation, ribosomal structure and biogenesis
  rplQ        Rv3456c   0.45            0.03   Information storage and processing: Translation, ribosomal structure and biogenesis
  truA        Rv3455c   0.45            0.03   Information storage and processing: Translation, ribosomal structure and biogenesis
  infB        Rv2839c   0.46            0.02   Information storage and processing: Translation, ribosomal structure and biogenesis
  rplT        Rv1643    0.47            0.04   Information storage and processing: Translation, ribosomal structure and biogenesis
  Rv0881      \-        1.68            0.07   Information storage and processing: Translation, ribosomal structure and biogenesis
  gnd2        Rv1122    0.44            0.03   Metabolism: Carbohydrate transport and metabolism
  Rv2039c     \-        0.46            0.02   Metabolism: Carbohydrate transport and metabolism
  Rv1200      \-        1.63            0.04   Metabolism: Carbohydrate transport and metabolism
  pgk         Rv1437    1.65            0.07   Metabolism: Carbohydrate transport and metabolism
  Rv2471      \-        1.83            0.12   Metabolism: Carbohydrate transport and metabolism
  Rv2040c     \-        2.11            0.19   Metabolism: Carbohydrate transport and metabolism
  panB        Rv2225    0.52            0.03   Metabolism: Coenzyme metabolism
  Rv1335      \-        1.66            0.04   Metabolism: Coenzyme metabolism
  nadA        Rv1594    1.73            0.09   Metabolism: Coenzyme metabolism
  cobU        Rv0254c   1.78            0.03   Metabolism: Coenzyme metabolism
  appC        Rv1623c   0.42            0.05   Metabolism: Energy production and conversion
  Rv0247c     \-        0.54            0.05   Metabolism: Energy production and conversion
  ctaC        Rv2200c   0.37            0.10   Metabolism: Energy production and conversion
  Rv1257c     \-        1.74            0.04   Metabolism: Energy production and conversion
  pks18       Rv1372    0.44            0.04   Metabolism: Lipid metabolism
  fadD32      Rv3801c   0.47            0.01   Metabolism: Lipid metabolism
  Rv3815c     \-        1.77            0.08   Metabolism: Lipid metabolism
  deoC        Rv0478    0.53            0.05   Metabolism: Nucleotide transport and metabolism
  dgt         Rv2344c   0.59            0.04   Metabolism: Nucleotide transport and metabolism

^a^ Genes were classified as differentially expressed if the Cy5/Cy3 intensity ratios were outside the range of 0.67--1.5.

molecules-18-01728-t003_Table 3

###### 

qRT-PCR results demonstrating 4-deoxybostrycin-induced differential expression of *M. tuberculosis* H37Rv genes.

  Gene names   Rv1518   gnd2      Rv1212c   appC    rpsS    nadA    dgt     prfB    cmaA1    Rv0247c   Rv3815c   Rv0922
  ------------ -------- --------- --------- ------- ------- ------- ------- ------- -------- --------- --------- --------
  Ratio ^a^    0.642    0.539     1.187     0.83    0.793   1.137   1.243   1.01    0.964    0.739     0.933     0.961
               Rv0282   Rv3673c   Rv3132c   cobU    narL    rplT    cysA    rplQ    fadD32   Rv2040c   Rv1354c   Rv1200
               1.989    9.219     0.742     0.919   0.937   0.728   0.805   0.807   1        0.817     0.801     0.924
               Rv3044   Rv1372    Rv1257c   htpX    pgk     ctaC    infB    rpsD    ogt      Rv2264c   Rv0907    Rv1335
               15.46    0.59      1.023     0.846   0.708   1.069   0.787   0.733   0.826    1.275     0.878     1.26

^a^ The ratio was calculated by dividing the amplified gene copies of 4-deoxybostrycin-treated bacteria by the amplified gene copies of untreated bacteria; genes were classified as differentially expressed if the ratios were outside the range of 0.67--1.5.
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###### 

The primers of qRT-PCR.

  Gene names                               PCR product length (bp)   Forward primer (5′→3′)   Reverse primer (5′→3′)
  ---------------------------------------- ------------------------- ------------------------ -------------------------
  Rv1518                                   145                       gcctcaaccgaaaccacaa      gcgaaagccattccgaca
  Rv0282                                   117                       ccaacgcacgcaccactt       cggatgttctcccgcttca
  gnd2                                     111                       gccaaaggtggacacgactg     ctgagacaactcacgcaacgag
  Rv3044                                   102                       gggtttgacgccgcagtt       ccgacaccacgcaggttatt
  Rv3673c                                  99                        cacgatctcgtcggcactg      cgggtcgcaaatgtgatgc
  Rv1372                                   69                        ggtggtagtccgcagtagtttc   cgaaataagcgttgagttggtc
  Rv0247c                                  91                        ctgttgtagacggaggatgacg   cggagacgaaagctgtggc
  cobU                                     94                        cagatgtacctcatcgcagacg   ggtggtgccatcccattctt
  htpX                                     70                        gactggcatcctgcgtatcct    gacgtgagacagctcgtggc
  rpsS                                     147                       acttcatcggccatacctttgc   gcttgctctttcggtcgtctttt
  narL                                     68                        cacgttcaccgagccactca     gcgacgaccacccgttattt
  Rv0907                                   114                       acaacgtcgtgacctgggata    cggagcgatgcgagtagag
  Rv1200                                   112                       gcttcggcttcgtctacctg     cacagcagtccacccagca
  Rv1212c                                  126                       tcgtcggcgtcgtaatgc       gctgggtatcgtaaacctggaa
  Rv1335                                   86                        tatccattccgaccatcctgc    gctgatgacggcacccaag
  pgk                                      84                        aaggcggacagcattgtgatt    cagcagcgatgtgccaacc
  nadA                                     133                       catgttgcaccagcttcgc      ttcgtcggcaccctctacc
  Rv2040c                                  117                       caccagcaagatggcgaaca     ggtcccgagacggctacctat
  ctaC                                     137                       agccaaacttccaattccactg   caccgtcataccgttcctcatc
  Rv2264c                                  104                       gccaccgaagtcgcatacc      agccactgtcactgctccct
  dgt                                      93                        tgcgttccaaccgaccct       ccgctgcgttcaataccg
  cysA                                     85                        gcgcttacggatcttcaacc     cggattcgtcttccagcacta
  infB                                     132                       ccgagtagtagcggatctcca    gcggcattaccgaaaccaa
  prfB                                     119                       cgcttgcgttccaacaact      gtgcggctcacccacatt
  Rv3132c                                  94                        acaaggctggtcgctgaatg     tcgatggtctggtggaggc
  cmaA1                                    68                        tcaggaaacgagcgaaggtg     cgggttgcatccgaaagag
  rplQ                                     92                        gaggtcaccgtcttctcccg     ggctacacccgtatcatcaaaa
  rpsD                                     117                       acgccgttgacgttgaaatg     actgctgaagatcctcgaaagc
  fadD32                                   107                       tcagtccgaagtggcgaaga     gaacctccagcggcaagat
  Rv3815c                                  60                        gcctgggatggtccttggt      cgattgtgcccgtcgttgt
  ogt                                      242                       cgaaataagcgttgagttggtc   ggcatggctcggtgttga
  Rv1354c                                  441                       ctggcggtatgtaggtcttgc    ggcgggtttgttgacttcg
  Rv0922                                   387                       ccgcaatgggtttggtcg       ggtggatttggctggaggc
  Rv1257c                                  354                       ggtccatgatttcgccgtac     caatacccacccgttgctg
  10Sa RNA (control)                       85                        ttcgctatgcctctgctcg      ggactcctcgggacaacca
  MPT70 (control)                          135                       tgaccagcatcctgacctacc    cggcgttaccgaccttga
  diaminopimelate decarboxylase(control)   142                       ccttactgctattcgctgtcga   ggcacgggtcacctcactt

[^1]: These authors contributed equally to this work.
